Most lately, it's been discovered that conolidine and the above derivatives act about the atypical chemokine receptor 3 (ACKR3. Expressed in related parts as classical opioid receptors, it binds to some big range of endogenous opioids. Not like most opioid receptors, this receptor acts for a scavenger and does not activate a next messenger process